.

Deeper Knowledge, Faster

  • Find suppliers and generic API sources
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Express Scripts
Deloitte
US Army
Cantor Fitzgerald
AstraZeneca
Fuji
Medtronic
Chinese Patent Office
Moodys
Fish and Richardson

Generated: July 26, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Which drugs does patent 6,958,161 protect, and when does it expire?


Patent ► Subscribe protects DORYX and DORYX MPC and is included in one NDA. There have been five Paragraph IV challenges on Doryx.

Summary for Patent: ► Subscribe

Title: Modified release coated drug preparation
Abstract:A modified release preparation having one or more coated core elements, each core element including an active ingredient and having a modified release coating, wherein a stabilising coat is provided between each core element and its modified release coating so that, upon in vitro dissolution testing, the amount of active ingredient released at any time on a post-storage dissolution profile is within 40 percentage points of the amount of active ingredient released at any time on a pre-storage dissolution profile.
Inventor(s): Hayes; David (Rostrevor, AU), LoPore; Angelo (Magill, AU), Lukas; Stefan (Manningham, AU), Quinn; Eugene (Prospect, AU)
Assignee: F H Faulding & Co Limited (Underdale, AU)
Application Number:10/120,376
Patent Claim Types:
see list of patent claims
Formulation; Compound; Use; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Mayne Pharma
DORYX
doxycycline hyclate
TABLET, DELAYED RELEASE;ORAL050795-006Dec 19, 2014ABRXYesNo► Subscribe► SubscribeY TO TREAT OR PREVENT INFECTIONS CAUSED BY SUSCEPTIBLE BACTERIA USING DELAYED-RELEASE TABLETS CONSISTING OF DOXYCYCLINE HYCLATE COATED PELLETS IN A TABLET
Mayne Pharma
DORYX
doxycycline hyclate
TABLET, DELAYED RELEASE;ORAL050795-001May 6, 2005ABRXYesNo► Subscribe► SubscribeY TO TREAT OR PREVENT INFECTIONS CAUSED BY SUSCEPTIBLE BACTERIA USING DELAYED-RELEASE TABLETS CONSISTING OF DOXYCYCLINE HYCLATE COATED PELLETS IN A TABLET
Mayne Pharma
DORYX
doxycycline hyclate
TABLET, DELAYED RELEASE;ORAL050795-004Apr 11, 2013ABRXYesNo► Subscribe► SubscribeY TO TREAT OR PREVENT INFECTIONS CAUSED BY SUSCEPTIBLE BACTERIA USING DELAYED-RELEASE TABLETS CONSISTING OF DOXYCYCLINE HYCLATE COATED PELLETS IN A TABLET
Mayne Pharma
DORYX
doxycycline hyclate
TABLET, DELAYED RELEASE;ORAL050795-002May 6, 2005ABRXYesNo► Subscribe► SubscribeY TO TREAT OR PREVENT INFECTIONS CAUSED BY SUSCEPTIBLE BACTERIA USING DELAYED-RELEASE TABLETS CONSISTING OF DOXYCYCLINE HYCLATE COATED PELLETS IN A TABLET
Mayne Pharma
DORYX
doxycycline hyclate
TABLET, DELAYED RELEASE;ORAL050795-003Jun 20, 2008ABRXYesNo► Subscribe► SubscribeY TO TREAT OR PREVENT INFECTIONS CAUSED BY SUSCEPTIBLE BACTERIA USING DELAYED-RELEASE TABLETS CONSISTING OF DOXYCYCLINE HYCLATE COATED PELLETS IN A TABLET
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Harvard Business School
Fish and Richardson
Cipla
Express Scripts
McKinsey
QuintilesIMS
Mallinckrodt
Dow
Medtronic
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot